Abbott Laboratories (ABT) : Marshwinds Advisory Co scooped up 3 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 30,203 shares of Abbott Laboratories which is valued at $1,237,719.Abbott Laboratories makes up approximately 0.62% of Marshwinds Advisory Co’s portfolio.
Other Hedge Funds, Including , First Premier Bank boosted its stake in ABT in the latest quarter, The investment management firm added 2,844 additional shares and now holds a total of 9,970 shares of Abbott Laboratories which is valued at $408,571. Abbott Laboratories makes up approx 0.31% of First Premier Bank’s portfolio.First Financial Bank N.a. – Trust Division boosted its stake in ABT in the latest quarter, The investment management firm added 18,150 additional shares and now holds a total of 156,392 shares of Abbott Laboratories which is valued at $6,803,052. Abbott Laboratories makes up approx 1.26% of First Financial Bank N.a. – Trust Division’s portfolio.Lvm Capital Management Ltdmi boosted its stake in ABT in the latest quarter, The investment management firm added 30,674 additional shares and now holds a total of 64,149 shares of Abbott Laboratories which is valued at $2,741,728. Abbott Laboratories makes up approx 0.87% of Lvm Capital Management Ltdmi’s portfolio.
Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.